Oulu Mentalcare Oy
- Address
- Isokatu 8 B 8, 90100 Oulu, Finland
Oulu Mentalcare Oy - Mental Health Research Center
Oulu Mentalcare Oy is a specialized clinical research facility dedicated to advancing the understanding and treatment of psychiatric disorders. The center focuses on evaluating innovative therapeutic approaches for mental health conditions, with particular expertise in conducting pivotal Phase 3 clinical trials that assess both short-term efficacy and long-term safety outcomes.
- Major Depressive Disorder treatment studies investigating novel kappa opioid receptor antagonists
- Generalized Anxiety Disorder research evaluating flexible-dose therapeutic regimens
- Extended safety and tolerability assessments spanning up to 52 weeks of treatment
The center has established significant expertise in mood and anxiety disorders, conducting both short-term efficacy trials and comprehensive long-term extension studies. Their research portfolio includes evaluation of novel pharmacological mechanisms, including kappa opioid receptor antagonism for depression, as well as emerging treatments for Generalized Anxiety Disorder. With experience in randomized, double-blind, placebo-controlled study designs, Oulu Mentalcare Oy contributes valuable data to the development of next-generation psychiatric medications aimed at improving outcomes for patients with debilitating mental health conditions.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 3 by active trials.
- 1Intra-Cellular Therapies Inc.2active
lock +2 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Intra-Cellular Therapies Inc.2trials
lock +3 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 107 other sites in Finland
Therapeutic Area Benchmark — Finland
Select a therapeutic area to compare against other sites in Finland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Finland
Market Share
Country: Finland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Oulu Mentalcare Oy
lock Showing 1 of 10 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 2/3, Randomized, Double-blind, Parallel-group, Placebo-controlled, Flexible-dose, Multicenter Study to Evaluate the Efficacy and Safety of SEP 363856 in the Treatment of Adults with Generalized Anxiety Disorder | Otsuka Pharmaceutical Development & Commercialization Inc. | Phase IV | Not Recruiting | Sep 2023 | Sep 2025 |
IMP list
lock Showing 1 of 6 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| 1-[6-Ethyl-8-Fluoro-4-Methyl-3-(3-Methyl-1,2,4-Oxadiazol-5-Yl)Quinolin-2-Yl]-N-(Oxan-4-Yl)Piperidin-4-Amine | 2 | Unknown | 2024-07-18 | 2024-09-30 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.